{
    "clinical_study": {
        "@rank": "70522", 
        "arm_group": {
            "arm_group_label": "neoadjuvant FOLFOXIRI", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Objective tumour response rate to FOLFOXIRI to pre-operative therapy."
        }, 
        "brief_title": "Colon Neoadjuvant FOLFOXIRI Study", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Rectal Cancer", 
        "condition_browse": {
            "mesh_term": "Rectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >= 18 years of either sex.\n\n          -  ECOG performance status 0-1\n\n          -  Measurable disease by RECIST 1.1 criteria.\n\n          -  Histologically confirmed rectal adenocarcinoma (defined as either mid-  or low rectal\n             cancer that is located within 12 cm from the anal verge OR below the peritoneal\n             reflection) that is previously untreated.\n\n          -  'High risk' rectal cancer, or rectal cancers that are considered marginally operable\n             where there is a significant risk of positive surgical margin:\n\n               -  T3 (low-lying tumour at or below the levators) or T4, or\n\n               -  Tumour infiltrating perirectal fat, or\n\n               -  Any T-stage (T1-4) and node-positive tumour (invading surrounding structures or\n                  peritoneum)\n\n          -  Adequate bone marrow, renal and hepatic function as defined by: absolute neutrophil\n             count >= 1.5 x 109/L, hemoglobin >= 9 g/L, platelets >= 100 x 109/L, calculated\n             creatinine clearance >= 55 ml/min, total bilirubin =<1.5 x the upper limit of normal,\n             alanine aminotransferase (ALT) =<2.5 upper limit of normal.\n\n        Exclusion Criteria:\n\n          -  Known distant metastasis, even if the metastasis has been resected.\n\n          -  History of another invasive malignancy within the last 5 years, except for treated\n             basal cell carcinoma of the skin, cervical intraepithelial neoplasia, or non-invasive\n             DCIS of the breast.\n\n          -  Upper rectal cancer that is located above the peritoneal reflection.\n\n          -  Primary tumour associated with any one of the following features:\n\n               -  Frank intestinal obstruction, or\n\n               -  Endoscope unable to pass through the tumour's lumen plus worsening local\n                  obstructive symptoms. Note: Patients with such features should be assessed by\n                  the surgical team regarding stomal bypass prior to study enrolment. Such\n                  patients can still be considered for study enrolment after undergoing stomal\n                  bypass.\n\n          -  Known hypersensitivity reaction to the study drugs (i.e. fluoropyrimidine,\n             irinotecan, oxaliplatin)\n\n          -  Known peripheral neuropathy of grade 2 or more in severity.\n\n          -  Patients who have received an experimental anticancer therapy within the last 28\n             days.\n\n          -  Previous pelvic radiotherapy. Previous oxaliplatin or irinotecan for the treatment of\n             colon or rectal cancer\n\n          -  Patient with hip prosthesis\n\n          -  Major surgery within the last 28 days. Exception: Any patient who underwent stomal\n             bypass for obstructing primary tumour within the last 14 days are still eligible, as\n             long as the patient has sufficiently recovered from the surgery at the investigator's\n             discretion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941641", 
            "org_study_id": "COL021"
        }, 
        "intervention": [
            {
                "arm_group_label": "neoadjuvant FOLFOXIRI", 
                "intervention_name": "neoadjuvant FOLFOXIRI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "neoadjuvant FOLFOXIRI", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Capecitabine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "contact": {
                "email": "brigette@clo.cuhk.edu.hk", 
                "last_name": "Brigette MA, MD, FRCP", 
                "phone": "2632 2118"
            }, 
            "contact_backup": {
                "email": "jane@clo.cuhk.edu.hk", 
                "last_name": "Jane KOH, RN", 
                "phone": "2632 1142"
            }, 
            "facility": {
                "address": {
                    "city": "Hong Kong", 
                    "country": "Hong Kong"
                }, 
                "name": "Department of Clinical Oncology"
            }, 
            "investigator": {
                "last_name": "Brigette MA, MD,FRCP", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Hong Kong"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Neoadjuvant FOLFOXIRI Followed by Concurrent Capecitabine and Radiotherapy for High Risk Rectal Cancer", 
        "overall_contact": {
            "email": "brigette@clo.cuhk.edu.hk", 
            "last_name": "Brigette MA, MD, FRCP", 
            "phone": "2632 2118"
        }, 
        "overall_contact_backup": {
            "email": "jane@clo.cuhk.edu.hk", 
            "last_name": "Jane Koh, RN", 
            "phone": "2632 1142"
        }, 
        "overall_official": {
            "affiliation": "Chinese University of Hong Kong", 
            "last_name": "Brigette MA, MD, FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective tumour response rate", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941641"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese University of Hong Kong", 
            "investigator_full_name": "CCTU", 
            "investigator_title": "Comprehensive Cancer Trials Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumour regression grade", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "pathologic complete response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Rate of circumferential resection margin (CRM) clearance", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Rate of tumour downstaging", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "disease-free survival, relapse-free survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Time to local (and distant) recurrence", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Number of patients with 30-day post-operative mortality", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Compliance to study treatment", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Number of response to neoadjuvant therapy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Chinese University of Hong Kong", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese University of Hong Kong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}